As­traZeneca cel­e­brates a PhI­II PARP suc­cess for Lyn­parza, putting pres­sure on Tesaro ri­val

As­traZeneca dropped one very big, tan­ta­liz­ing clue this morn­ing that will de­ter­mine the fate of its PARP in­hibitor Lyn­parza (ola­parib). As ri­val PARPs come up …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER